Shanghai Junshi Biosciences Co., Ltd.

Junshi Biosciences, officially known as Shanghai Junshi Biosciences Co., Ltd., is an innovation-driven biopharmaceutical company headquartered in Shanghai, China. Established in December 2012, its core business focuses on the discovery, development, and commercialization of novel therapies. The company's mission is to provide patients with world-class, trustworthy, affordable, and innovative drugs that address unmet medical needs.

The company's research and development efforts span five core therapeutic areas: oncology, autoimmune diseases, metabolic diseases, neurological diseases, and infectious diseases. Key products include Toripalimab (marketed as Tuoyi in China and LOQTORZI internationally), an anti-PD-1 monoclonal antibody, as well as adalimumab, mindeudesivir hydrobromide, and ongericimab. Junshi Biosciences has developed several innovation platforms, including those for monoclonal antibodies (mAb), antibody-drug conjugates (ADC), bispecific antibodies, and nucleic acid drugs.

Junshi Biosciences is recognized as the first Chinese firm to receive approval for an anti-PD-1 monoclonal antibody, Toripalimab, by China's National Medical Products Administration (NMPA) and subsequently by the U.S. Food and Drug Administration (FDA) in 2023 for nasopharyngeal carcinoma. The company also received European Commission approval in 2024 for nasopharyngeal carcinoma and esophageal squamous cell carcinoma. Recent developments include NMPA approvals for Toripalimab in various indications and a licensing collaboration with Fosun Wanbang for roconkibart (anti-IL-17A mAb). The leadership team includes Xiong Jun as Chairman, Jianjun Zou as CEO, and Ning Li as Vice Chairman.